Natco Pharma Q3 ResultsS: Natco Pharma Ltd. recorded a sharp decline of 37.75 percent in consolidated net profit for the December quarter, mainly affected by the recession in the export of yoga. The company stood at the consolidated net profit 132.4 crore Q3 FY2025, from a drop According to a regulatory filing, 212.7 crore was recorded in the respective quarter of the previous financial year.
The integrated revenue of the pharmaceutical firm fell due to operation 474.8 crore in Q3 FY2025, from below 758.6 crore in the year-old period, shows a reduction of 37.4 percent in earnings.
Prior to interest, taxes, depreciation and refinement (EBITDA), the company’s earnings saw a huge decline of 85.5 percent year-by-year, which fell 38.8 crore in Q3 FY2025 268.1 crore in Q3 FY2024. This steep decline in operating profits led to a significant contraction in the Ebitda margin, which fell from 3717 base points 35.3 percent to 8.2 percent in the respective quarter of the previous year. During this period, the challenges faced by the company were underlined by contraction in the margin.
Total expenses were recorded for the quarter 487.4 crores, marking the deficiency from 539.3 crore in the same period last year. Despite the fall in expenses, the company’s overall performance remained under pressure due to weak revenue creation.
An important factor behind the earnings was a steep decline in the export exports, which fell 285.8 crore in Q3 FY2025 605.6 crore in Q3 FY2024. Meanwhile, the sales of domestic formulation also recorded a decline 96.1 crore in Q3 FY2025 compared to According to the company’s investor presentation, 99.4 crores in the same period last year.
Dividend
In a separate development, the board of directors of the company declared a third interim in a meeting held on Wednesday. Dividend Of 1.50 per equity share 2 every financial year for 2024-25. Natco Pharma announced that the record date for determining eligible shareholders to get interim dividends has been set for Tuesday, February 18, 2025. The company further stated that payment of the announced interim dividend will start from February 28, 2025.
